PFM Health Sciences, LP Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001442756
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q2 2024 · 76 positions · Total reported value $1.97B · Top-10 concentration 47.3% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 75.8% · 24 new · 28 cut · 39 exited
Active Share (vs S&P 500): 96.6% · vs QQQ: 99.7% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q2 2026 → Q3 2026): -4.9% · vs SPY -7.0% · Prev Value $1.14B — last quarter positions weighted by this quarter price moves · ranking
Est. QTD Return (Q3 2026 → newest close): +2.3% · vs SPY +0.2% · Latest Value $978.49M — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking
In its Q2 2024 13F filing, PFM Health Sciences, LP disclosed 76 equity positions with a combined reported value of $1.97B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 47.3% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.
The largest disclosed positions as of Q2 2024 were LLY ($270.39M), CYTK ($95.20M), QQQ ($89.79M). By sector, the heaviest allocations are Health Care 84.2%, Industrials 3.8%. Versus the prior quarter, allocation shifted toward Health Care (+3.9pp) and away from Technology (-1.4pp), Industrials (-2.2pp).
Versus the prior quarter, PFM Health Sciences, LP opened 24 new positions, trimmed 28 and fully exited 39, a turnover rate of 75.8% of positions. The portfolio's overlap with the prior quarter was 78% of names.
The largest new positions opened in Q2 2024 were QQQ ($89.79M), XBI ($55.12M), AMGN ($25.32M).
Of the 39 positions fully exited versus the prior quarter, the largest were TLT ($49.49M), LEGN ($41.19M), ZBH ($39.64M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q2 2024)
- QQQ INVESCO QQQ TR · $89.79M
- XBI SPDR SERIES TRUST · $55.12M
- AMGN AMGEN INC · $25.32M
- JNJ JOHNSON & JOHNSON · $18.83M
- INSM INSMED INC · $16.17M
- KROS KEROS THERAPEUTICS INC · $1.52M
- WAY WAYSTAR HLDG CORP · $752.50K
Fully Exited (vs previous quarter)
- TLT ISHARES TR · prev qtr: $49.49M
- LEGN LEGEND BIOTECH CORP · prev qtr: $41.19M
- ZBH ZIMMER BIOMET HOLDINGS INC · prev qtr: $39.64M · history
- AVTR AVANTOR INC · prev qtr: $34.35M
- FXI ISHARES TR · prev qtr: $28.02M
- VEEV VEEVA SYS INC · prev qtr: $27.55M · history
- WST WEST PHARMACEUTICAL SVSC INC · prev qtr: $20.26M
- ARKK ARK ETF TR · prev qtr: $12.13M
Insider Transactions (Form 4)
Latest PFM Health Sciences, LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.
Fund Profile
PFM Health Sciences, LP is an SEC-registered 13F filer based in San Francisco, CA, United States. As of Q2 2026 it reported 96 US equity positions with a combined value of $1.14B. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).
Firm Snapshot
- Headquarters: SAN FRANCISCO, CA, United States
- SEC registration: 801-69012 (status: Approved), registered 2008-04-10
- Regulatory AUM (Form ADV): $1.27B as of 2026-03-31
- Client mix (by RAUM): pension and profit-sharing plans 100%
- Manages 4 private funds, of which 2 hedge funds
- Website: pfmhealthsciences.com
Portfolio Structure
- 96 positions · $1.14B reported value (Q2 2026)
- Top 10 holdings = 34.6% of reported value
- Largest position: ASND (ASCENDIS PHARMA A/S) at 5.4%
- Average position size: $11.89M
Sector Tilt
- Health Care 92.9%
- Industrials 5.1%
- Consumer Staples 1.2%
- (classified holdings cover 100% of value)
Quarterly Activity
- Q2 2026: 32 new, 24 added, 40 reduced, 14 exited
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
298.64K | $270.39M | 13.71% | Hold | |
| 2 |
|
1.76M | $95.20M | 4.83% | Reduce | |
| 3 |
|
187.40K | $89.79M | 4.55% | New | |
| 4 |
|
589.41K | $78.41M | 3.98% | Hold | |
| 5 |
|
596.26K | $73.82M | 3.74% | Hold | |
| 6 |
|
148.85K | $69.77M | 3.54% | Hold | |
| 7 |
|
403.86K | $69.27M | 3.51% | Hold | |
| 8 |
|
740.26K | $68.38M | 3.47% | Hold | |
| 9 |
|
137.33K | $61.09M | 3.10% | Add | |
| 10 |
|
97.50K | $56.94M | 2.89% | Hold | |
| 11 |
|
594.50K | $55.12M | 2.80% | New | |
| 12 |
|
125.34K | $46.83M | 2.38% | Hold | |
| 13 |
|
124.84K | $40.11M | 2.03% | Add | |
| 14 |
|
598.51K | $39.68M | 2.01% | Hold | |
| 15 |
|
213.98K | $39.57M | 2.01% | Hold | |
| 16 |
|
114.30K | $38.89M | 1.97% | Add | |
| 17 |
|
467.43K | $37.63M | 1.91% | Hold | |
| 18 |
|
86.83K | $37.34M | 1.89% | Hold | |
| 19 |
|
116.53K | $36.53M | 1.85% | Add | |
| 20 |
|
63.65K | $35.20M | 1.78% | Add | |
| 21 |
|
185.11K | $33.31M | 1.69% | Add | |
| 22 |
|
125.52K | $31.36M | 1.59% | Hold | |
| 23 |
|
131.38K | $30.70M | 1.56% | Reduce | |
| 24 |
|
55.25K | $29.94M | 1.52% | Hold | |
| 25 |
|
420.16K | $28.38M | 1.44% | Add | |
| 26 |
|
348.11K | $26.81M | 1.36% | Add | |
| 27 |
|
52.40K | $26.69M | 1.35% | Add | |
| 28 |
|
231.01K | $26.19M | 1.33% | Add | |
| 29 |
|
81.03K | $25.32M | 1.28% | New | |
| 30 |
|
111.85K | $23.65M | 1.20% | Hold | |
| 31 |
|
70.09K | $20.84M | 1.06% | Hold | |
| 32 |
|
18.00M | $20.10M | 1.02% | Add | |
| 33 |
|
128.82K | $18.83M | 0.95% | New | |
| 34 |
|
453.15K | $18.74M | 0.95% | Reduce | |
| 35 |
|
311.98K | $17.22M | 0.87% | Add | |
| 36 |
|
241.31K | $16.17M | 0.82% | New | |
| 37 |
|
2.97M | $15.60M | 0.79% | Reduce | |
| 38 |
|
15.00M | $14.91M | 0.76% | Hold | |
| 39 |
|
70.70K | $14.34M | 0.73% | Reduce | |
| 40 |
|
837.00K | $13.71M | 0.69% | Add | |
| 41 |
|
860.82K | $13.62M | 0.69% | Hold | |
| 42 |
|
472.54K | $12.48M | 0.63% | Hold | |
| 43 |
|
170.40K | $11.67M | 0.59% | Add | |
| 44 |
|
4.67M | $11.03M | 0.56% | Add | |
| 45 |
|
10.52M | $10.26M | 0.52% | Add | |
| 46 |
|
7.75M | $9.99M | 0.51% | Add | |
| 47 |
|
29.97K | $8.40M | 0.43% | Hold | |
| 48 |
|
387.36K | $7.95M | 0.40% | Reduce | |
| 49 |
|
3.24M | $7.91M | 0.40% | Add | |
| 50 |
|
4.08M | $6.70M | 0.34% | Reduce | |
FAQ
What did PFM Health Sciences, LP buy in 2024-Q2?
In its 2024-Q2 13F filing, PFM Health Sciences, LP reported 76 equity positions worth $1.97B in aggregate; its largest disclosed positions were LLY ($270.39M), CYTK ($95.20M), QQQ ($89.79M).
How large is PFM Health Sciences, LP's portfolio?
PFM Health Sciences, LP reported $1.97B of long equity holdings across 76 positions as of 2024-Q2. Top-10 holdings account for 47.3% of reported value.
What is PFM Health Sciences, LP's investment style?
HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.